Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | In-line → Underperform | Evercore ISI | |
| 8/9/2024 | $5.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 7/3/2024 | $5.00 | Market Perform → Outperform | Leerink Partners |
| 4/2/2024 | $6.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/13/2024 | $23.00 → $7.00 | Outperform → Market Perform | Leerink Partners |
| 2/12/2024 | $25.00 → $7.00 | Outperform → In-line | Evercore ISI |
| 2/12/2024 | Outperform → Perform | Oppenheimer | |
| 2/12/2024 | Mkt Outperform → Mkt Perform | JMP Securities |
10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.
Gainers Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. Can Fite Biofarma (AMEX:
Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target from $7 to $2.
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the
AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a
Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously
Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7th Annual Evercore HealthCONx Conference, December 3-5, 2024 Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, December 4 at 8:20am ET Oppenheimer's Movers in Rare Disease Summit, December 12, 2024 Members of management will be available for 1X1 meetings on Thursday, December 12, 2024 A webcast of the Ev
Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug candidate with statistically favorable patient reported outcome (PRO)-based improvement in treatment-refractory Mycobacterium avium Complex (TR-MAC) population Company plans to meet with FDA to gain alignment on a development path for epetraborole, including potentially reinitiating a Phase 3 clinical study, while advancing its boron chemistry pipeline Achieved 50% reduction in expenditures through strategic realignment of operations Cash, cash equivalents, and investments of $93.4 million a
Grant from the Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria. "We are appreciative of the Gates Foundation's continued support as we advance our joint effort to discover new drugs for tuberculosis and malaria, with the goal of combating drug resistance and shortening treatment duration for th